Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aprepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 15/20 | 1.00 |
| ▸ | TACR3 | P29371 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | FPR1 | P21462 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aprepitant SCHEMBL15219399 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL3232579 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL263983 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL12228634 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL4790281 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL23420636 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL3232587 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL12063232 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL12903476 | 1.00 | TACR1 (1.00) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL12903485 | 0.95 | TACR1 (0.91) | TACR1TACR3NR3C1CYP3A4FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 694 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| EP-4604948-A2 | USE OF ANTAGONISTS OF NEUROKININ-1 RECEPTOR AND NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HERPESVIRIDAE | The Regents of the University of Colorado, a body corporate (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4543919-A1 | COMBINATION THERAPIES | Alligator Bioscience AB (SE) | 2025-04-30 | — | — | EP | claimed |
| WO-2025085662-A1 | COMPOUNDS FOR TOCOLYTIC USE | VANDERBILT UNIVERSITY (US) | 2025-04-24 | — | — | WO | claimed |
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024088808-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2024-05-02 | — | — | WO | claimed |
| WO-2023247050-A1 | COMBINATION THERAPIES | ALLIGATOR BIOSCIENCE AB (SE) | 2023-12-28 | — | — | WO | claimed |
| WO-2023247660-A1 | COMBINATION THERAPIES | ALLIGATOR BIOSCIENCE AB (SE) | 2023-12-28 | — | — | WO | claimed |
| US-20230381092-A1 | Method for obtaining a purified substance from bee venom and anti-ageing cosmetic product comprising the purified substance | MORAGA FUENTES HUGO PATRICIO (CL) | 2023-11-30 | — | — | US | claimed |
| CN-116669717-A | Long-acting in-situ forming/gelling composition | 美国人福制药公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022082327-A1 | METHOD FOR OBTAINING A PURIFIED SUBSTANCE FROM BEE VENOM AND ANTI-AGEING COSMETIC PRODUCT COMPRISING THE PURIFIED SUBSTANCE | MORAGA FUENTES HUGO PATRICIO (CL) | 2022-04-28 | — | — | WO | claimed |
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| WO-2007088483-A1 | AMORPHOUS AND CRYSTALLINE FORMS OF APREPITANT AND PROCESSES FOR THE PREPARATION THEREOF | GLENMARK PAHRMACEUTICALS LIMITED (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007039883-A2 | PROCESS FOR PREPARATION OF APREPITANT | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | TACR1 1/4885TACR3 116/4885NR3C1 626/4885 |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | NLN, DCX, CNTN1 | TACR1 1882/4885TACR3 713/4885NR3C1 846/4885 |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TACR1 670/4885TACR3 823/4885NR3C1 1214/4885 |
| US-20260146036-A1 | CRYSTALLINE FORMS | PRKCD, CCT8, CRYZ | TACR1 4410/4885TACR3 4261/4885NR3C1 4554/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | TACR1 95/4885TACR3 280/4885NR3C1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.